E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular EventsEVOLVE

- Inclusion:≥ 18 years of age - Treated with maintenance hemodialysis - PTH ≥ 300 pg/mL (31.8 pmol/L) - serum calcium ≥ 8.4mg/dL (2.1 mmol/L) - Ca x P ≥ 45 mg2*/dL2 (3.63 mmol2/L2)

- Exclusion: - Parathyroidectomy in the 12 weeks before the date of informed consent - Received therapy with cinacalcet within 3 months of randomization - Hospitalization within 12 weeks of randomization for any of the following events: a. Myocardial ischemia b. Unstable angina c. Heart Failure (HF) (including any unplanned presentation to a health care facility that would require mechanical intervention [i.e., unplanned dialysis treatment]) d. Peripheral vascular disease (other than dialysis vascular access revision) e. Stroke - History of seizure within 12 weeks prior to randomization - Scheduled date for kidney transplant from a known living donor - Anticipated parathyroidectomy within 6 months after randomization *in all instances, the 2 refers to squared.